Salvat laboratories will move all their production from Esplugues to Alcalá de Henares

BarcelonaSignificant step for Salvat laboratories. The Catalan family-owned pharmaceutical company has decided to concentrate all its production capacity at the factory it has in Alcalá de Henares, in Madrid. The move from the Esplugues de Llobregat plant will be progressive until 2030, according to its new strategic plan approved in July. The company is open to negotiating geographical mobility possibilities for the staff "responsibly, maintaining dialogue with the legal representatives of the workers during the different phases of the transition".

At the same time, the family group highlights that it will maintain its corporate headquarters, central offices, and research and development (R&D) activity in Esplugues de Llobregat. Salvat frames the initiative as "a change in industrial model". The essential objective is to "strengthen competitiveness and have a more robust, efficient industrial platform prepared to accompany long-term growth plans". With this goal, the company will progressively concentrate its manufacturing capabilities for solids, liquids, and sterile liquids at its industrial complex in Alcalá de Henares.

This evolution will allow "integrating the group's main production and operational capabilities in a single location, following its roadmap defined until 2030 and progressively transferring the manufacturing currently carried out in Esplugues de Llobregat, where it will maintain its corporate headquarters, central offices, and R&D activity". The group, which has already exceeded 100 million euros in turnover, expects to launch a drug in the United States and another in China this same year.

The Alcalá de Henares plant is consolidating itself as one of Salvat's main strategic assets and as the hub industrial hub of the group for the next stage of growth. The industrial complex in the Madrid town has a plant dedicated to the manufacturing of non-sterile solids and liquids and a second plant specialized in the production of sterile liquids, both in Blow-Fill-Seal (BFS) technology and in multidose formats. The latter, authorized by the FDA (the pharmaceutical sector regulator in the USA) to supply the North American market, has a production capacity of over 250 million vials per year.

Internal reorganization

The consolidation of the industrial platform is part of the transformation that Salvat is driving "to build a more agile, efficient and competitive organization, equipped with the necessary capabilities to respond to the growing demands of the pharmaceutical industry". To carry out this evolution, Salvat has initiated a process of geographical mobility for the positions in the operations area of Esplugues. The company will address this transition through a process of dialogue.

"The consolidation of our Alcalá de Henares plant represents a strategic decision for the future of Salvat and a decisive step in the execution of our 2030 Plan. We need an industrial platform capable of supporting our long-term ambitions," states Jordi Muntañola, CEO of Salvat. "We are aware that this transformation implies relevant changes for our organization, and we want to address them with responsibility, dialogue and the utmost respect for the people. We are building the foundations of the Salvat of the coming years," he adds.